Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | RRM1 | P23921 | 1/20 | 0.38 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17443624 | 0.90 | PDE4B (0.57) | PDE4B | |
| SCHEMBL17467022 | 0.90 | PDE4B (0.45) | PDE4BARJAK2GRM2GRM5 | |
| SCHEMBL17450888 | 0.90 | PDE4B (0.48) | PDE4BHPGDKDM4ERAB9ANPC1 | |
| SCHEMBL17450852 | 0.89 | PDE4B (0.45) | PDE4BARCHRM2CHRM1RRM1 | |
| SCHEMBL17443587 | 0.89 | PDE4B (0.51) | PDE4BJAK2 | |
| SCHEMBL17443803 | 0.88 | PDE4B (0.48) | PDE4BARGRM2 | |
| SCHEMBL17443748 | 0.88 | PDE4B (0.47) | PDE4BHPGDRAB9ANPC1MAPT | |
| SCHEMBL17450834 | 0.86 | KDM1A (0.46) | — | |
| SCHEMBL17456903 | 0.86 | KDM1A (0.46) | — | |
| SCHEMBL17443649 | 0.86 | PDE4B (0.46) | PDE4BARCHRM2CHRM1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3415509-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE INHIBITORS | Grünenthal GmbH (DE) | 2018-12-19 | — | — | EP | disclosed |
| US-9315490-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-9315490-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-9315490-B2 | 2,5-substituted pyrimidines | GRUENENTHAL GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-20160024053-A1 | Novel 2,5-Substituted Pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-20160024053-A1 | Novel 2,5-Substituted Pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-20160024053-A1 | Novel 2,5-Substituted Pyrimidines | GRUENENTHAL GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| WO-2016008592-A1 | NOVEL 2,5-SUBSTITUTED PYRIMIDINES AS PDE INHIBITORS | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024053-A1 | Novel 2,5-Substituted Pyrimidines | PDE4B, PDE4A, PDE12 | PDE4B 1/4885HPGD 325/4885AR 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.